Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
Status:
Completed
Trial end date:
2018-07-27
Target enrollment:
Participant gender:
Summary
Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and
safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).
Phase:
Phase 2
Details
Lead Sponsor:
Jean Yuh Tang
Collaborators:
Epidermolysis Bullosa Research Partnership Menlo Therapeutics Inc. Vyne Therapeutics Inc.
Treatments:
Neurokinin A Neurokinin-1 Receptor Antagonists Serlopitant Substance P